Multiple Myeloma

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›

A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›

Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment. Read More ›

Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone. Read More ›

On October 25, 2022, the FDA accelerated the approval of teclistamab-cqyv (Tecvayli; Janssen Biotech), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. Read More ›

Data from the IMAGE study support real-world use of isatuximab in patients with relapsed/refractory multiple myeloma, with findings similar to those reported for ICARIA-MM. Read More ›

Patient-reported outcomes with ciltacabtagene autoleucel are consistent with clinical findings and support its use in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›

Iberdomide, a novel cereblon E3 ligase modulator, in combination with dexamethasone showed encouraging results in a multicohort, open-label, phase 1/2 trial. Read More ›

Iberdomide and mezigdomide have shown to be more potent than traditional immunomodulators and may have potential as new oral agents in multiple myeloma. Read More ›